Citius Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
Citius Pharmaceuticals, Inc. is a specialty biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The company focuses on therapeutic products that address unmet medical needs, primarily utilizing reformulations of previously approved drugs to reduce development risk. Its lead product candidate is LYMPHIR (denileukin diftitox-cxdl), an FDA-approved targeted immunotherapy for persistent or recurrent cutaneous T-cell lymphoma (CTCL), which was launched in the U.S. in December 2025 through its majority-owned subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR). Citius's late-stage pipeline also includes Mino-Lok, an antibiotic lock solution to treat catheter-related bloodstream infections, and Halo-Lido, a topical formulation for hemorrhoids.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Driving physician adoption, expanding patient access, and securing formulary inclusions for LYMPHIR (denileukin diftitox-cxdl) in the U.S. market.
Expected impact: Targeting an underserved U.S. cutaneous T-cell lymphoma (CTCL) market estimated to exceed $400 million.
Advancing the regulatory pathway toward a New Drug Application (NDA) submission for Mino-Lok, a novel antibiotic lock solution designed to salvage infected central venous catheters.
Expected impact: Establishing the first and only FDA-approved therapy to salvage infected indwelling catheters, avoiding costly and risky catheter replacement procedures.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquired to expand the critical care product pipeline, bringing in the foundational asset Mino-Lok.
Financial impact: Formed the basis of Citius's late-stage clinical pipeline, driving R&D expenses and future commercial potential.
Strategic Partnerships
Establishes international access to LYMPHIR across 12 European markets (including Greece, Cyprus, Malta, Bulgaria, Romania, and Croatia) through country-specific Named Patient Programs (NPPs).
Terms: Exclusive distribution rights for specified territories; detailed financial terms undisclosed.
Provides up to $25 million in non-dilutive debt capital to support the ongoing commercialization of LYMPHIR.
Terms: $10 million funded at close on May 6, 2026, with up to $15 million available in subsequent tranches subject to revenue and liquidity milestones.